Roche's $4.8B deal for Spark cleared by FTC after long delay

The Federal Trade Commission on Monday cleared Roche's $4.8 billion buyout of Spark Therapeutics, bringing to a close a 10-month investigation that had spurred concerns acquisitions of other gene therapy biotechs would be similarly scrutinized.